Analyst Price Targets — HAE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 13, 2026 2:40 pm | Anthony Petrone | Mizuho Securities | $70.00 | $57.39 | TheFly | Haemonetics price target lowered to $70 from $80 at Mizuho |
| February 6, 2026 2:45 pm | — | Robert W. Baird | $81.00 | $61.40 | TheFly | Haemonetics price target lowered to $81 from $99 at Baird |
| February 6, 2026 12:37 pm | — | Barrington | $94.00 | $65.02 | TheFly | Haemonetics price target raised to $94 from $93 at Barrington |
| February 6, 2026 12:36 pm | — | Mizuho Securities | $80.00 | $65.02 | TheFly | Haemonetics price target lowered to $80 from $90 at Mizuho |
| January 12, 2026 12:37 pm | — | Barrington | $93.00 | $82.03 | TheFly | Haemonetics price target raised to $93 from $90 at Barrington |
| December 17, 2025 11:57 am | — | Mizuho Securities | $90.00 | $81.11 | TheFly | Haemonetics price target raised to $90 from $75 at Mizuho |
| December 15, 2025 2:16 pm | — | Robert W. Baird | $99.00 | $80.33 | TheFly | Haemonetics price target raised to $99 from $87 at Baird |
| November 14, 2025 9:22 am | Andrew Cooper | Raymond James | $90.00 | $73.91 | StreetInsider | Haemonetics (HAE) PT Raised to $90 at Raymond James |
| November 6, 2025 6:30 pm | — | BTIG | $88.00 | $66.20 | TheFly | Haemonetics price target raised to $88 from $85 at BTIG |
| August 7, 2025 4:49 pm | Mike Matson | Needham | $68.00 | $55.64 | TheFly | Haemonetics price target lowered to $68 from $84 at Needham |
Latest News for HAE
Bio-Rad Laboratories (NYSE: BIO - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Risk and Volatility Bio-Rad Laboratories has a beta
Haemonetics (NYSE: HAE - Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Risk and Volatility Haemonetics has a beta of 0.36,
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026.
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular…
Invenomic sold 498,317 shares of Haemonetics Corporation in the fourth quarter. The quarter-end position value decreased by $24.29 million due to the sale of all the fund's shares.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HAE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.